NASDAQ:PODD - Insulet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$104.08 +0.18 (+0.17 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$103.90
Today's Range$101.2150 - $106.22
52-Week Range$70.80 - $108.90
Volume257,544 shs
Average Volume721,104 shs
Market Capitalization$6.21 billion
P/E Ratio2,081.60
Dividend YieldN/A
Beta1.5
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$563.82 million
Cash Flow$0.3211 per share
Book Value$3.75 per share

Profitability

Net Income$3.29 million

Miscellaneous

Employees1,169
Market Cap$6.21 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings data on Thursday, May, 2nd. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.02 by $0.05. The medical instruments supplier had revenue of $159.56 million for the quarter, compared to the consensus estimate of $154.66 million. Insulet had a net margin of 2.37% and a return on equity of 7.01%. The business's revenue for the quarter was up 29.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.11) EPS. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Insulet.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its FY 2019 earnings guidance on Thursday, May, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $667-690 million, compared to the consensus revenue estimate of $680.47 million.Insulet also updated its Q2 2019 guidance to EPS.

What price target have analysts set for PODD?

10 Wall Street analysts have issued 12 month price objectives for Insulet's shares. Their predictions range from $90.00 to $115.00. On average, they expect Insulet's stock price to reach $103.80 in the next twelve months. This suggests that the stock has a possible downside of 0.3%. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

Has Insulet been receiving favorable news coverage?

News coverage about PODD stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insulet earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), Splunk (SPLK), Tandem Diabetes Care (TNDM), EXACT Sciences (EXAS), Alibaba Group (BABA), ServiceNow (NOW), Veeva Systems (VEEV), Netflix (NFLX), Paypal (PYPL) and Canopy Growth (CGC).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)
  • Mr. Wayde D. McMillan, Exec. VP & CFO

Who are Insulet's major shareholders?

Insulet's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.78%), Wellington Management Group LLP (12.42%), Primecap Management Co. CA (8.24%), William Blair Investment Management LLC (3.59%), Frontier Capital Management Co. LLC (3.28%) and Artisan Partners Limited Partnership (2.33%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, John A Fallon, Michael L Levitz, Michael P Spears and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Wellington Management Group LLP, First Trust Advisors LP, OppenheimerFunds Inc., Columbus Circle Investors, Eagle Asset Management Inc., Carillon Tower Advisers Inc. and Osterweis Capital Management Inc.. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which institutional investors are buying Insulet stock?

PODD stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Frontier Capital Management Co. LLC, Artisan Partners Limited Partnership, KAMES CAPITAL plc, Jennison Associates LLC, Federated Investors Inc. PA, Moody National Bank Trust Division and American National Insurance Co. TX. Company insiders that have bought Insulet stock in the last two years include Charles Alpuche and James C Mullen. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $104.08.

How big of a company is Insulet?

Insulet has a market capitalization of $6.21 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  541 (Vote Outperform)
Underperform Votes:  477 (Vote Underperform)
Total Votes:  1,018
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel